As DJ-1 is highly overexpressed in various cancers and positively contributes to cell survival, the selective inhibition or degradation of DJ-1 by small molecule inhibitors or proteolysis-targeting chimeras (PROTACs) [86] may become a novel anti-cancer strategy, with minor side effects. The gene discussed is PARK7; the disease is cancer.